Should a Patient With a BRAF-Mutated Tumor Receive Targeted vs ICI Neoadjuvant Therapy?

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Integrating Immune Checkpoint Therapy Into the Management of Resectable Melanoma

Should a Patient With a BRAF-Mutated Tumor Receive Targeted vs ICI Neoadjuvant Therapy?

ReachMD Healthcare Image
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
2.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
  • Overview

    This program is designed to raise awareness and close knowledge gaps for medical oncologists, surgeons, dermatologists, oncology nurses, and oncology pharmacists regarding the expanding use of ICIs to treat patients with melanoma. It addresses investigational neoadjuvant and adjuvant therapy with ICIs, especially in the earlier stages of the disease. It includes the scientific rationale driving research, clinical trial surrogate endpoints, predictive biomarkers, mechanisms of disease resistance under investigation, efficacy and safety data from recent pivotal clinical trials, and clinical management challenges. The program allows busy clinicians to hear from the experts on critical takeaways from research studies and implications for current practice, such as treatment selection and effective management of treatment-related AEs.

  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, surgeons, dermatologists, oncology nurses, oncology pharmacists, and other members of the interprofessional team who are involved in the management of patients with melanoma.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    1. Identify patients with resectable melanoma who may benefit from treatment with neoadjuvant and adjuvant ICIs
    2. Describe the surrogate endpoints being used in clinical trials to assess efficacy with ICIs, and the biomarkers used in research and practice for predicting response to ICIs, in perioperative neoadjuvant and adjuvant settings
    3. Apply data from clinical trials of ICIs in neoadjuvant and adjuvant settings to inform treatment strategies for patients with resectable melanoma
    4. Identify strategies for managing risks and complications of toxicities and other potential complications (e.g., pseudoprogression and hyperprogression) in these settings
    5. Recognize the outstanding issues regarding optimal dose, timing, and schedule
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 2.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

  • Faculty Disclosure of Commercial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs. 
    The following faculty have reported relationships with ineligible companies:

    Brian Gastman, MD, co-chair for this educational event, is a contract researcher for Alkermes, Merck, NeoImmuneTech, and Instill Bio; and receives consulting fees from Castle Biosciences, Quest Imaging, Merck, BMS, Iovance, and Instill Bio. 

    Jeffrey S. Weber MD, PhD, co-chair for this educational event, is a contract researcher for BMS, Merck, Pfizer, Moderna, GSK, Genentech, AstraZeneca, Alkermes, and Regeneron; has an ownership interest in Biond, Instil Bio, OncoC4, and Evaxion; receives royalties from Iovance on a patent for TIL growth; is a patent holder on a CTLA4 biomarker and TIL growth filed by Moffitt Cancer Center, and a PD1 biomarker patent filed by Bidesix; and receives consulting fees from BMS, Merck, Pfizer, Moderna, GSK, Genentech, AstraZeneca, Alkermes, Regeneron, Biond Biologics, Instil Bio, OncoC4, and Evaxion. 

    Michael T. Tetzlaff MD, PhD, faculty for this educational event, has no relevant financial relationships with ineligible companies.

  • Planners and Managers Disclosure List

    The following planners/reviewers/managers have disclosed:

    Megan Reimann, PharmD, BCOP, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, planner for this educational event, has no relevant financial relationships with ineligible companies.

    TotalCME, Inc. planners and managers have no relevant commercial relationships to disclose.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restrictions, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by independent educational grants from Bristol Myers Squibb and Merck Sharp & Dohme LLC.

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

  • Fee Statement

    This activity is FREE to all participants.

  • Instructions

    During the period 9/30/2022 through 9/30/2023, registered participants wishing to receive continuing education credit for this activity must follow these steps:
    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule21 Sep 2023